[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aging":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,294,0,25,[9,52,78,109,135,157,182,213,237,265,288,317,342,364,384,406,426,449,480,503,527,550,571,595,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100646079","efficacy-of-cbt-i-with-adjuvant-melatonin-in-older-adults-chronic-insomnia-100646079",false,"NCT07695246","Efficacy of CBT-I With Adjuvant Melatonin in Older Adults Chronic Insomnia","Efficacy of Cognitive Behavioural Therapy for Insomnia With Adjuvant Melatonin Treatment in Older Adults With Chronic Insomnia: A Randomised Controlled Trial","SOAM","Inclusion Criteria:\n\n1. Chinese aged ≥ 60.\n2. Provision of written informed consent.\n3. Having a DSM-5 diagnosis of insomnia disorder (i.e., having difficulty initiating sleep, maintaining sleep, or early morning awakening at least three times a week for at least three months, with clinically significant impairment or distress).\n4. Having a score of \\> 14 on the ISI, indicating clinical insomnia.\n\nExclusion Criteria:\n\n1. Having a current diagnosis or a history of manic or hypomanic episodes, schizophrenia spectrum disorders, neurodevelopmental disorders, neurocognitive disorders, organic mental disorders, intellectual disabilities, or substance abuse or dependence.\n2. Having a progressive medical condition directly related to the onset and course of insomnia (e.g., cancer, chronic pain).\n3. Undergoing treatment for diseases known to affect sleep (e.g., chemotherapy).\n4. Having an untreated sleep disorder that may disrupt sleep continuity and quality (e.g., sleep-disordered breathing) except for insomnia disorder.\n5. Having mild to significant cognitive impairment, defined by having a score of \\\u003C 22 on MOCA.\n6. Concurrent and regular use of extraneous melatonin or melatonin agonist (e.g., ramelteon).\n7. Receiving concurrent psychological treatment for insomnia.\n8. Meeting potential contraindications for melatonin (e.g., undergoing dialysis) or concurrently using medications that have a potential drug interaction with melatonin (e.g., anticoagulant and anti-platelet).\n9. Being a night shift worker.","ALL","60 Years",{"count":21,"type":22},183,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study tests the efficacy of cognitive behavioural therapy for insomnia (CBT-I) with or without adjunct melatonin in older adults with insomnia. Adults aged 60 or above with chronic insomnia will be randomly assigned to one of three groups: (1) CBT-I plus nightly melatonin, (2) CBT-I plus nightly placebo tablet, or (3) sleep health psychoeducation plus nightly placebo tablet. All group sessions occur weekly for four weeks.",[28,29,30],"Insomnia","Aging","Sleep Disorders",[28,32,33,34,35,36,37,38],"Elderly","CBT","Melatonin","Circadian Rhythm","Sleep","Randomised controlled trial","Older adults","RECRUITING","2026-08-20",{"date":42,"type":43},"2026-08-21","ACTUAL",{"date":45,"type":43},"2026-08-01",{"date":47,"type":22},"2029-08-01",{"name":49,"class":50},"The University of Hong Kong","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":18,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":51},"100600558","amyloid-pet-imaging-in-the-baltimore-longitudinal-study-of-aging-100600558","NCT07099053","Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging","Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)","* INCLUSION\u002FEXCLUSION CRITERIA:\n* Participants are men and women 55 years and older drawn from the BLSA sample and thus, represent the gender\u002Fethnic characteristics of this study group. Enrollment is defined as the initial imaging session of the planned longitudinal study.\n* Inclusion criteria: BLSA participants who do not meet exclusion criteria and have had or agreed to have an MRI under the BLSA study.\n* Participants who lack capacity to consent will not be enrolled in the study. If the participant loses capacity to consent over the course of follow-up they will be removed them from the study. Competency to consent is assessed as part of the BLSA visit and we will not include people who are not competent to provide consent.\n\nEXCLUSION CRITERIA:\n\n* Preexisting central nervous system diseases\n* Weight over 300 lbs.\n* Active metastatic cancer (except basal cell cancer)\n* Implanted electronic hearing devices\n* Breast Cancer with radiation treatment\n* Lymphoma\n* Pacemaker\n* Brain tumor\n* Shrapnel\n* Schizophrenia\n* Bipolar disorder\n* Epilepsy\n* Language barrier that makes it difficult to understand participant.\n* Aneurisms greater than 3mm\n* Aneurysm clips\n* Parkinson s disease\u002FPD medications\n* Huntington s disease\n* Severe Endocrinopathy- treated thyroid conditions ok; treated, controlled diabetes ok. (exclude HbA1c over 8 which is poorly controlled diabetes)\n* Diagnosis of dementia or mild cognitive impairment\n* Younger than 55 years of age\n* Pregnancy\n* Ineligible for MRI\n* History of stroke or documented TIAs requiring hospitalization\n* Known brain vascular malformations or adenomas\n* History of significant radiation exposure\n* Those with a Blessed score of 4 or more with the BLSA will be reviewed at a research diagnostic case conference to rule out dementia diagnoses prior to enrollment.",true,"55 Years","110 Years",{"count":63,"type":22},400,"OBSERVATIONAL","Background:\n\nSome people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities. Amyloids are groups of proteins that develop in the brain and increase in number as people age. Researchers want to use imaging scans to track amyloids in people s brains over time. Their goal is to find out if any changes are related to cognitive decline or other medical issues.\n\nObjective:\n\nTo learn how amyloids may affect brain structure and function as people age.\n\nEligibility:\n\nPeople aged 55 years and older who are enrolled in the Baltimore Longitudinal Study of Aging.\n\nDesign:\n\nParticipants will have imaging scans and other tests every 1 to 4 years, depending on their age. Those 80 and older will be scanned yearly. These scans will be done during regular BLSA visits.\n\nThe scans will be positron emission tomography and computed tomography (PET CT). Participants will be given fluid through a tube inserted into a vein in their arm. The fluid is a tracer that will cause the amyloids to light up in the images. Then they will lie on a bed with their head inside a PET CT scanner. They will lie still for about 30 minutes.\n\nParticipants will have tests to assess their memory and other mental skills. They will answer questions about their mood and daily life. These tests will take about 40 minutes to complete; they may be done in person or by phone.\n\nParticipants will give a contact number for someone who can answer questions about the participant s daily routine. These questions may be answered in person or by phone.\n\nParticipants will be in this study for 5 years.",[29],[68,69],"Amyloid","PET",{"date":42,"type":43},{"date":72,"type":22},"2026-08-26",{"date":74,"type":22},"2029-12-12",{"name":76,"class":77},"National Institute on Aging (NIA)","NIH",{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":59,"sex":18,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":97,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":51},"100582854","ketone-ester-and-salt-keas-in-older-adults-100582854","NCT06868719","Ketone Ester And Salt (KEAS) in Older Adults","Ketone Supplementation as a Strategy to Reduce the Negative Health Effects of High Dietary Salt in Older Adults","KEAS-O","Inclusion Criteria:\n\n* Between the ages of 60-85\n* Resting blood pressure no higher than 150\u002F90\n* BMI below 35 kg\u002Fm2 (or otherwise healthy)\n* Free of any metabolic disease (diabetes or renal), pulmonary disorders (COPD, severe asthma, or cystic fibrosis), cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular)\n* Do not have any precluding medical conditions that prevent participants from exercising (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis) or giving blood (e.g., blood thinners)\n\nExclusion Criteria:\n\n* High blood pressure - greater than150\u002F90 mmHg\n* Obesity (BMI \\> 30 kg\u002Fm2)\n* History of metabolic disease (diabetes or renal disease), pulmonary disorders (e.g., COPD, severe asthma, \\& cystic fibrosis), and cardiovascular disease (peripheral vascular, cardiac, or cerebrovascular).\n* Medical issues that prevent safe exercise (i.e., cardiovascular issues, or muscle\u002Fjoint issues including painful arthritis)\n* Medical issues that prevent giving blood (e.g., blood thinners).\n* Current smoking, using smokeless tobacco, or vaping (within past 12 months)\n* Current pregnancy","50 Years","85 Years",{"count":89,"type":22},35,[25],"Most Americans consume excess dietary salt based on the recommendations set by the American Heart Association and Dietary Guidelines for Americans. High dietary salt impairs blood pressure control by affecting systemic blood vessels and the kidneys. These changes contribute to excess salt consumption being associated with increased risk for chronic kidney disease and cardiovascular disease, the leading cause of death in America. Salt is particularly deleterious in older adults who are more likely to exhibit salt-sensitive hypertension. However, salt consumption remains high in the United States. Thus, there is a critical need for strategies to counteract the effects of high dietary salt as consumption is likely not going to decrease. One promising option is ketones, metabolites that are produced in the liver during prolonged exercise and very low-calorie diets. While exercise and low-calorie diets are beneficial, not many people engage in these activities. Limited evidence indicates that ketone supplements improve cardiovascular health in humans. Additionally, published rodent data indicates that ketone supplements prevent high salt-induced increases in blood pressure, blood vessel dysfunction, and kidney injury. Our human pilot data also indicates that high dietary salt reduces intrinsic ketone production, but it is unclear whether ketone supplementation confers humans' protection against high salt similar to rodents. Therefore, the investigators seek to conduct a short-term high-dietary salt study to determine whether ketone supplementation prevents high dietary salt from eliciting increased blood pressure, blood vessel dysfunction, and kidney injury\u002Fimpaired blood flow. The investigators will also measure inflammatory markers in blood samples and isolate immune cells that control inflammation. Lastly, the investigators will also measure blood ketone concentration and other circulating metabolites that may be altered by high salt, which could facilitate novel therapeutic targets to combat high salt.",[93,94,29,95,96],"Salt; Excess","Hypertension","Inflammation","Blood Pressure",[96,98,29,95,99],"Salt","Cardiovascular Disease","2026-08-18",{"date":102,"type":43},"2026-08-19",{"date":104,"type":43},"2025-03-06",{"date":106,"type":22},"2027-12-31",{"name":108,"class":50},"Indiana University",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":59,"sex":18,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":51},"100631899","imat-quality-in-aging-100631899","NCT07506681","IMAT Quality in Aging","Targeting Intramuscular Adipose Quality in Aging","Inclusion Criteria:\n\n* Rapid Assessment of Physical Activity scores between 3 and 5\n* Able to don and doff the weighted vest\n* Access to a smart phone and ability to navigate the phone to enter and manage a zoom intervention\n* Commitment and availability to attend a virtual 40-minute intervention 3x per week for 12 weeks\n\nExclusion Criteria:\n\n* Contraindications to radiation exposure (e.g. Women who are pregnant, previous high radiation exposure)\n* Bleeding disorders\n* Lower extremity trauma\u002Fsurgery\u002Finjury or neuropathy that would impact muscle structure and function or ability to complete exercise intervention\n* Diabetes mellitus, cardiovascular disease, peripheral vascular disease, cancer, stage 4 hypertension, anemia, connective tissue disorder\n* Neurological disorder (e.g. stroke, Parkinson's disease, multiple sclerosis, spinal cord injury)\n* Medications: insulin, glucagon-like peptide-1 (GLP1) agonists, sex hormone replacement therapy, chronic NSAIDs, anticoagulation therapy, cholesterol lowering medications such as statins\n* Unable to safely perform the progressive resistance exercise (e.g. Vestibular or balance issues that make performing the intervention unsafe, severe osteoporosis or general fragility that limits weighted vest tolerance)","65 Years","80 Years",{"count":119,"type":22},16,[25],"This study will test the central hypothesis that fat within the muscle, or intramuscular adipose tissue (IMAT), exhibits elevated damage and pro-inflammatory signaling with aging, both of which are reduced by progressive resistance exercise (PRE). Sixteen older adults 65-80 years old will be recruited and complete a 12 week calf PRE intervention. Calf muscle strength, composition (measured by computed tomography) and muscle biopsies will be collected before and after the intervention. Histology, transcriptomic and secretomic tests will be completed to assess signs of damage and inflammation.",[29],[124,125],"aging","muscle","NOT_YET_RECRUITING","2026-08-17",{"date":100,"type":43},{"date":130,"type":22},"2026-10-01",{"date":132,"type":22},"2028-01",{"name":134,"class":50},"Washington University School of Medicine",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":59,"sex":18,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":4,"leadSponsor":156,"locationsCount":51},"100075199","baltimore-longitudinal-study-of-aging-100075199","NCT00233272","Baltimore Longitudinal Study of Aging","The Baltimore Longitudinal Study of Aging (BLSA)","* INCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If any of these conditions develop after this time, the participant remains in the study. In particular, participants who develop cognitive, motor or psychiatric conditions are retained in the study, although they are excluded from specific testing in which their underlying health condition is an exclusion criteria. Participants that refuse genetic testing and storage at Visit 1 will not be eligible to participate in the study.\n\n* Age greater than or equal to 20 years of age\n* Weigh less than or equal to 300lbs and\u002For body mass index (BMI) is less than or equal to 40\n* Do not have established genetic diseases\n* Are able to perform daily self- care without assistance\n* Are able to walk independently for at least 400 meters without assistance and without developing symptoms\n* Are able to perform normal activities of daily living without shortness of breath (walking or climbing stairs)\n* Do not have cognitive impairment based on screening tests and in the absence of any drug treatment\n* Do not have a history of cardiovascular disease (including angina, myocardial infarction, congestive heart failure, cerebrovascular diseases, uncontrolled hypertension)\n* Do not have a history of diabetes (requiring any medical treatment other than diet and exercise)\n* Do not have active (any activity in the last 10 years) cancer, except for locally limited basal or squamous cell cancer\n* Do not have clinically significant hormonal dysfunction (Laboratory values out of range despite supplementation and\u002For drug treatment)\n* Do not have a history of neurological diseases or birth defects (other than minor anatomical abnormalities, which do not affect physical and\u002For cognitive function)\n* Do not have a history of kidney or liver disease (associated with reduced kidney or liver function)\n* Do not have a history of severe gastrointestinal (G.I.) diseases\n* Do not have muscle-skeletal conditions due to diseases or traumas (that cause pathological weakness and\u002For chronic pain)\n* Do not have a history of severe psychiatric conditions (associated with behavioral problems or requiring chronic medical treatment)\n* Do not have any medical condition that requires absolute and continuous need for long term treatment with antibiotics, corticosteroids, immunosuppressors, H2 blockers and\u002For proton pump inhibitors, or pain medications\n* Do not have important sensory deficits (legally blind and\u002For any condition that precludes the participant from being tested with standard neuropsychological tests or providing informed consent)\n* Able to read and speak English\n* Do not have joint replacements due to arthritic changes (joint replacements due to previous trauma are ok) or do not have 2 or more joint replacements for any reason\n* Do not meet any exclusionary criteria for 3T MRI and agrees to perform the test\n* Agree to genetic (DNA\u002FRNA) sample collection, analysis, and storage at Visit 1\n\nEXCLUSION CRITERIA:\n\nThese criteria pertain to the Screening Visit and Visit 1. If conditions considered as exclusion criteria for study entry develop any time after the this, the participant remains in the study.\n\nExclusion Criteria Based on Laboratory Assessment:\n\n* HIV virus infection\n* Hepatitis B or C\n* Syphilis\n* WBC \\> 12,000\u002FmcrL\n* Platelets \\\u003C 100,000 or \\>600,000 \u002FmcrL\n* Hemoglobin \\\u003C 11 g\u002FdL\n* Creatinine \\>1.5 mg\u002Fdl or calculated creatinine clearance \\\u003C 50 cc\u002Fmin\n* Bilirubin \\> 1.5 mg\u002Fdl (unless higher levels can be ascribed to Gilbert s disease)\n* ALT, AST or alkaline phosphatase twice the normal serum concentration\n* Corrected calcium \\\u003C 8.5 or \\> 10.7 mg\u002Fdl\n* Albumin \\\u003C 3.1 g\u002Fdl","20 Years","120 Years",{"count":145,"type":22},10000,"Background:\n\n\\- The Baltimore Longitudinal Study of Aging (BLSA) is a clinical research program on human aging that began in 1958. Volunteers of different ages join the study when they are healthy, and have follow-up visits for life. Visits last for multiple days. Participants are evaluated for many physical elements as well as for brain function. Physical tests are given. Information on mood, personality, and social aspects of life is also collected. This program has contributed more than any other research project to our understanding of aging.\n\nObjectives:\n\n\\- To characterize the many aspects of the aging process and learn how people can successfully adapt to aging.\n\nEligibility:\n\n\\- Healthy individuals at least 20 years old.\n\nDesign:\n\n* Participants will receive a booklet and video describing the tests they will take.\n* During a 3-day visit at the study hospital, participants will take the following tests:\n* Urine will be collected for 24 hours. Blood samples will be taken. A small piece of muscle tissue may be collected by a needle.\n* A medical questionnaire and a physical exam will be given.\n* Participants hearts will be tested, including with blood pressure tests and electronic monitors. They will breathe into a tube to test their lungs.\n* Participants will perform several exercises, including treadmill walking.\n* Vision, hearing, and taste will be tested.\n* Bone and joint X-rays may be taken.\n* Imaging tests will be given, such as an MRI.\n* Participants will answer questions to test their mental abilities.\n* Participants will return for follow-up visits every few years for life. The tests listed above will be given at every visit.",[29],[149,150,151],"Frailty","Disease Processes","Natural History","2026-08-15",{"date":100,"type":43},{"date":155,"type":43},"2014-02-03",{"name":76,"class":77},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":59,"sex":18,"minAge":60,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":180,"locationsCount":51},"100605289","cognitive-motor-training-for-adadrd-prevention-100605289","NCT07160582","Cognitive-Motor Training for AD\u002FADRD Prevention","Innovative Cognitive-Motor Training for Prevention of AD\u002FADRD","Inclusion Criteria:\n\n1. Age: 55-90 years.\n2. No recent major surgery, bone fracture, or hospitalization (\\\u003C 3 months).\n3. Not on any sedative drugs.\n4. Can understand and communicate in English.\n5. Can walk without an assistive device for at least 1 block to ensure independent functioning.\n6. Identification of Mild Cognitive Impairment (MCI) based on Jak\u002FBondi criteria\n7. Visual acuity greater than or equal to 20\u002F40 with or without corrective lenses to ensure intact vision.\n\nExclusion Criteria:\n\n1. Participants will not proceed with the study if any of the following occurs at baseline measurement: 1) Heart Rate \\>85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \\> 160 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg during resting.\n2. Unable to stand for 5 minutes without an assistive device and walk for 10 m without an assistive device\n3. Complaints of shortness of breath, or uncontrolled pain (more than 3 out of 10 on Visual Analogue Scale), or if pulse oxygen drops less than 92% on the six-minute walk test (for endurance) to ensure that the participant can effectively participate without discomfort or injury during testing and training.\n4. Exhibits difficulty understanding the study information.\n5. Self-reported history or presence of any neurological, musculoskeletal, cardiorespiratory, or systemic disorders that significantly impact mobility or the ability to walk independently (without an assistive device).\n6. Self-reported disability (with or without an assistive device) to ensure independent functioning.\n7. Uncontrolled (not under any medications) hypertension to avoid cardiovascular complications during testing\u002Ftraining.\n8. Weight \\>220 lbs (harness weight threshold).","90 Years",{"count":166,"type":22},46,[25],"Alzheimer's disease and related dementias (AD\u002FADRD) greatly affect memory and daily activities in older adults. Mild Cognitive Impairment (MCI) is an early stage of dementia, affecting about 17% of older adults. People with MCI often show problems with gait and balance, which doubles their risk of falling compared to cognitively healthy peers. Falls can cause injuries, increase sedentary behavior, and reduce physical activity. This decline in activity can also speed up the progression from MCI to dementia. Exercise can help older adults make healthy lifestyle changes; however, most of the existing exercise programs focus mainly on physical movement rather than cognitive function. Therefore, the investigators developed a new program that uses computer vision and a cloud-based system to provide more scalable, engaging, and personalized cognitive-motor training for OAwMCI. The purpose of this study is to investigate the short- and long-term effects of a novel CogXergaming training (CXT) paradigm for improving the cognitive-motor function, physical activity, falls efficacy, and quality of life.",[170,29],"MCI",[172,173,174],"CogXergaming","Cognitive-motor interference","Dual-task","2026-08-14",{"date":100,"type":43},{"date":130,"type":22},{"date":179,"type":22},"2027-12-01",{"name":181,"class":50},"University of Illinois at Chicago",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":59,"sex":18,"minAge":116,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":4},"100652393","mitochondrial-intervention-for-resilience-in-older-adults-with-coenzyme-q10-100652393","NCT07772336","MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10","Mitochondrial Intervention for Resilience in Older Adults With Coenzyme Q10","MIRO-Q","Inclusion Criteria\n\n* Age 65 years or older.\n* Community-dwelling older adult.\n* Presence of signs of reduced biological resilience or prefrailty, defined by meeting at least one of the following criteria:\n\n  * Prefrailty according to the Fried frailty phenotype, defined as the presence of 1-2 of the following criteria: unintentional weight loss, self-reported exhaustion, reduced physical activity, slow walking speed, or reduced handgrip strength; or\n  * Reduced physical performance, defined as a Short Physical Performance Battery (SPPB) score of ≤9; or\n  * Increased functional vulnerability, defined as a Clinical Frailty Scale (CFS) score of ≥4.\n* Ability to understand the study procedures and comply with the study protocol.\n* Ability and willingness to provide written informed consent before participation.\n\nExclusion Criteria\n\n* Established frailty with severe functional impairment that would interfere with study participation or outcome assessment.\n* Advanced dementia or cognitive impairment preventing informed consent or reliable participation in study assessments.\n* Active malignant disease or ongoing cancer treatment.\n* Acute inflammatory disease or acute infection at the time of enrollment.\n* Acute or unstable medical condition that could substantially affect functional performance, cognitive assessment, or the safety of the intervention.\n* Any medical condition considered by the investigator to make participation inappropriate or unsafe.\n* Current use of CoQ10 supplementation at a dose that could interfere with assessment of the study intervention, unless discontinued for the predefined washout period.\n* Known hypersensitivity or intolerance to CoQ10 or any component of the study product.\n* Participation in another interventional clinical trial that could affect the outcomes of the present study.",{"count":191,"type":22},100,[25],"This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty.\n\nParticipants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The study will assess the effects of CoQ10 supplementation on mitochondrial functional resilience, chronic low-grade inflammation, metabolic health, physical performance, cognitive function, and objective measures of skin aging.\n\nThe study will also investigate whether baseline biological and functional characteristics can identify individuals who are more likely to benefit from CoQ10 supplementation. An exploratory aim is to develop a multidimensional composite index of biological resilience integrating molecular, biochemical, functional, and clinical measures of aging.\n\nThe study will provide evidence on whether a mitochondria-targeted intervention with CoQ10 may represent a potential strategy for improving functional resilience and reducing features of prefrailty in older adults.",[149,29,195,196,197],"Mitochondria Health","Skin Aging","Mitochondrial Dysfunction",[199,124,200,201,202,203,204],"frailty","older adults","Coenzyme Q10","mitochondrial dysfunction","geroscience","functional aging","2026-08-13",{"date":102,"type":43},{"date":208,"type":22},"2026-09",{"date":210,"type":22},"2027-02",{"name":212,"class":50},"University Medical Centre Ljubljana",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":59,"sex":18,"minAge":221,"maxAge":4,"enrollmentInfo":222,"targetDuration":223,"studyType":64,"phases":4,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":51},"100648308","artificial-intelligence-based-health-assessment-from-face-photographs---healthy-volunteer-study-100648308","NCT07719049","Artificial Intelligence-Based Health Assessment From Face Photographs - Healthy Volunteer Study","Artificial Intelligence-Based Phenotyping of Health From Photographs - Healthy Volunteer Study","FaceAge","Inclusion Criteria:\n\n* The protocol enrolls healthy volunteers from the adult (age 18 and above) general population. All races and genders will be included.\n\nExclusion Criteria:\n\n* Any skin condition or recent facial injury that could affect facial appearance.\n* Inability to follow study instructions or provide informed consent.\n* Taking new or strong medication on the day of image capture could potentially affect appearance or alertness.","18 Years",{"count":145,"type":22},"3 Years","The investigators aim to examine how FaceAge estimates (a measure of biological age based on facial features) change across different time points and identify factors that may influence these changes. This will help the investigators understand the consistency and reliability of the FaceAge algorithm and allow them to make improvements.",[29,226],"Facial Aging",[228,29,229],"Artificial Intelligence","Biomarkers of Aging",{"date":127,"type":43},{"date":232,"type":43},"2025-10-23",{"date":234,"type":22},"2027-10",{"name":236,"class":50},"Brigham and Women's Hospital",{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":59,"sex":18,"minAge":19,"maxAge":117,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":51},"100648206","phase-1-psilocybin-effects-on-healthy-aging-biomarkers-and-purpose-in-life-100648206","NCT07719088","Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life","An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life","LONG-LIFE","Inclusion Criteria:\n\n* English speaking and able to provide informed consent and complete study procedures\n* Medically healthy, as determined by the screening physician, with no significant medical conditions that would interfere with participation or affect the safety of the subject.\n\nExclusion Criteria:\n\n* History or presence of any psychiatric or medical condition that, in the opinion of the investigator, could pose a safety risk, interfere with participation, or confound study results.\n* Abnormal ECG at screening that may increase risk during participation (e.g., prolonged QTc, arrhythmias, or other clinically significant findings as determined by the study physician).\n* Unwilling or unable to discontinue medications that may interfere with study participation, as determined by the investigator.",{"count":246,"type":22},50,[248],"PHASE1","The LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose\u002Fmeaning in life in medically stable older adults.\n\nUp to 50 participants will be enrolled aged 60-80 who will be randomized with equal allocation to one of four intervention groups: (1) receipt of one 25 mg dose of psilocybin; (2) receipt of two 25 mg doses of psilocybin separated by four weeks; (3) receipt of three 25 mg doses, with each dose separated by four weeks; or (4) wait-list comparator condition that does not receive psilocybin. Biomarkers of aging, cognitive performance, and behavioral measures will be assessed at baseline and longitudinally over a 12-month follow-up period. The primary endpoint occurs at the Week 16 visit. Participants randomized to the wait-list condition will be offered a single 25 mg dose of psilocybin following conclusion of the 12-month follow-up period.\n\nFindings from this Phase I study will inform dose selection for a Phase II study should results indicate a potential impact of psilocybin on relevant study endpoints.",[29,251,229],"Longevity",[29,251,253,254,255,256,257],"Cognitive Function","Purpose","Meaning","Well-Being","Biomarkers",{"date":127,"type":43},{"date":260,"type":22},"2026-12",{"date":262,"type":22},"2028-12",{"name":264,"class":50},"Charles Raison",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":59,"sex":18,"minAge":116,"maxAge":117,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":51},"100518208","phase-2-the-mito-frail-trial-effects-of-mitoq-on-vasodilation-mobility-and-cognitive-performance-in-frail-older-adults-100518208","NCT06027554","The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults","Mito-Frail","Inclusion Criteria:\n\n* men and women aged 65-80 with a slow gait speed (0.4m\u002Fs based on a 4m walk) and\u002For mild cognitive impairment.\n* good cardiovascular health (not taking any blood pressure\u002Fflow\u002Fmetabolism altering medications)\n\nExclusion Criteria:\n\n* A vaccination in past two weeks\n* Recent acute infection three weeks prior to enrollment\n* Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy\n* Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids\n* Severe autoimmune disease requiring biological therapy\n* Major severe illness and\u002For Hospitalization in past 3 months\n* On warfarin or other medications that are considered a blood thinner\n* Recent fall or other conditions that will impair ability to complete and\u002For interpret mobility performance test\n* Known bleeding disorder\n* Any conditions that would impair the function to perform grip strength test\n* include advanced neurological disease, severe co-morbid disease, terminal illness with reduced life expectancy, severe disability, unintentional weight loss in last 12 months and participation in another study.\n* Diabetes patients requiring insulin (For reducing the risk that participants will have hypoglycemic episodes when fasting for study visits)\n* Baseline ECG QTc \\>450 ms in men and QTc \\>460 ms in women\n* Prior diagnosis of ventricular arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)",{"count":273,"type":22},60,[275],"PHASE2","The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and\u002For cognitive dysfunction. The main question\\[s\\] it aims to answer are:\n\n* To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction\n* To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels\n* To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.",[149,278,29],"Mild Cognitive Impairment","2026-08-10",{"date":281,"type":43},"2026-08-12",{"date":283,"type":43},"2024-10-07",{"date":285,"type":22},"2028-02-01",{"name":287,"class":50},"UConn Health",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":116,"maxAge":117,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":304,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":51},"100620441","effects-of-rehabilitative-exergame-training-on-foot-muscle-activity-balance-and-mobility-in-older-adults-100620441","NCT07357662","Effects of Rehabilitative Exergame Training on Foot Muscle Activity, Balance, and Mobility in Older Adults","Evaluation of the Effects of Rehabilitative Exergame Exercises on Foot Muscle Activation, Balance, and Mobility in Older Adults Using Surface Electromyography and Postural Sway Measurements","EXG-FOOT","Inclusion Criteria:\n\n* Aged 65 to 80 years\n* Having a minimum of 5 years of formal education\n* Ability to walk independently for at least 10 meters, with or without a walking aid if necessary\n* Having sufficient cognitive function for communication and participation, defined as a Mini-Mental State Examination (MMSE) score ≥26\n\nExclusion Criteria:\n\n* Body mass index (BMI ≥30 kg\u002Fm²)\n* Presence of central or peripheral nervous system disorders or use of medications that may affect balance\n* History of vestibular pathology\n* Lower extremity amputation, prior lower extremity surgery, or malignancy affecting the lower extremities\n* Presence of moderate to severe congenital heart disease, coronary artery disease, or cerebrovascular disease\n* Presence of visual, psychiatric, or cognitive impairments that could interfere with study participation or assessment procedures",{"count":297,"type":22},40,[25],"This study is designed as a randomized controlled trial. A total of 40 healthy older adults residing in private and public nursing homes and rehabilitation centers in Mersin will be enrolled. Participants will be randomly assigned to either the intervention group (Group 1) or the control group (Group 2).\n\nThe intervention group will receive rehabilitative interactive game-based exercise training, while the control group will receive functional balance exercise training. Both groups will participate in exercise sessions three times per week, with each session lasting 40 minutes, over a period of 8 weeks.\n\nParticipants will undergo pre- and post-intervention assessments, including:\n\ni) clinical tests and measurements for cognitive, functional, and balance evaluation; ii) surface electromyography (sEMG) measurements recorded during the Functional Reach Test (FRT); and iii) biomechanical measurements obtained via integrated inertial measurement unit (IMU) sensors (accelerometer and gyroscope) and the Becure game board.\n\nElectrophysiological and biomechanical data will be analyzed using statistical comparisons, correlation analyses, and regression models. Variables derived from time, frequency, and time-frequency domain analyses will be examined to identify potential sEMG and biomechanical biomarkers.",[29,301,302,303],"Foot Muscle Dysfunction","Sarcopenia","Age-Related Muscle Weakness",[305,38,306,307],"older adults, physical activity, interactive computer games, biomarkers, electrophysiology, biomedical signal processing","Biomedical signal processing","Physical activity","2026-08-09",{"date":310,"type":43},"2026-08-11",{"date":312,"type":43},"2026-06-01",{"date":314,"type":22},"2027-12-30",{"name":316,"class":50},"Tarsus University",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":59,"sex":18,"minAge":221,"maxAge":87,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":327,"briefSummary":328,"conditions":329,"keywords":331,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":51},"100437106","using-nicotine-to-reverse-age-related-auditory-processing-deficits-100437106","NCT04971954","Using Nicotine to Reverse Age-related Auditory Processing Deficits","Using Nicotine to Reverse Age-related Auditory Processing Deficits: Human Psychophysics and Electrophysiology","Nicotine","Inclusion Criteria:\n\n* between 18 and 85 years of age\n* non-smokers with a score of 0-2 out of 10 maximum on the Fagerström index of smoking dependency\n* cognitive performance within two standard deviations of the CERAD mean\n\nExclusion Criteria:\n\n* less than 18 or greater than 85 years of age\n* deafness or excessive hearing loss\n* smokers with a score between 3 and 10 on the Fagerström index of smoking dependency\n* history of psychiatric illness, neurological disorders, diabetes mellitus, renal failure, or cardiovascular disease\n* regular use of prescription medications (excluding oral contraceptives)\n* drug dependency",{"count":326,"type":22},48,[25],"The present study will evaluate the effects of both aging and nicotine on psychophysical tasks and electrophysiological measures. Nicotine will be administered to study participants in the form of gum that is available as an over-the-counter medication. The hypothesis is that nicotine will reverse the detrimental effects of aging on auditory processing. The proposed experiments will characterize the effects of nicotine and may eventually lead to improved treatments of hearing loss in a variety of patient populations and in healthy aging.",[330,29],"Auditory Perceptual Impairment",[332,333],"nicotine","biomarker","2026-08-06",{"date":279,"type":43},{"date":337,"type":43},"2022-02-01",{"date":339,"type":22},"2026-12-31",{"name":341,"class":50},"University of California, Irvine",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":59,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":51},"100636944","adjuvant-nitrate-to-boost-exercise-induced-health-benefits-in-older-adults-100636944","NCT07572266","Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults","BOOST-X","Inclusion Criteria:\n\n1. Male or female aged 60 years or older\n2. Free of chronic disease or disorder that would preclude full participation or have the potential to confound results\n3. No structured exercise program (2 or more bouts\u002Fwk) within previous 12 months\n4. Cognitively capable of providing informed consent\n\nExclusion Criteria:\n\n1. BMI ≥ 30.0 kg\u002Fm2\n2. Neurodegenerative disease\n3. Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and\u002For physical performance testing\n4. Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.\n5. Resting blood pressure \\\u003C90\u002F60 mmHg or \\>160\u002F95 mmHg\n6. Uncontrolled hypertension\n7. Any current cardiovascular disease or cardiopulmonary instability\n8. Recent cardiovascular event or procedure within the preceding 6 months\n\n   1. If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure\n   2. Any mechanical valve replacement that requires continuous warfarin anti-coagulation\n9. Anemia: Hgb \\\u003C11.0 (♂),10.0 (♂) gm\u002Fdl\n10. Diabetes with HgbA1c \\>7.0% or fasting blood glucose ≥ 130 mg\u002Fdl\n11. Liver disease with ALT \\> 52 U\u002Fl)\n12. Chronic kidney disease (eGFR \\\u003C 45)\n13. Any current infectious disease\n14. Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)\n15. Life expectancy \\\u003C 1 year Medications \u002F lifestyle\n16. Insulin sensitizing\u002Fblood glucose lowering agents such as metformin\n17. Currently on or have used GLP-1 agonist or other metabolic \u002F weight loss drug in previous 12 weeks\n18. Use of nitrate medications\n19. High dose statin (≥40 mg\u002Fd simvastatin equivalence)\n20. Chronic corticosteroids\n21. Testosterone or other anabolic\u002Fandrogenic hormone therapy\n22. Lidocaine allergy\n23. Regular tobacco use and\u002For vaping \\> 1\u002Fwk\n24. Use of cannabis \\> 1\u002Fwk\n25. Excessive alcohol consumption (3 drinks\u002Fd or 7 drinks\u002Fwk for females; 4 drinks\u002Fd or 14 drinks\u002Fwk for males)\n26. Use of illicit drugs (e.g., cocaine, opioids)\n27. Unable to commit to \\~4 months required to complete the study",{"count":350,"type":22},226,[25],"Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments to compromise intrinsic capacity and healthspan. Exercise is the only multipotent treatment with promise to mitigate many of the aging hallmarks, but there is substantial variability in individual exercise responsiveness. Thus, the investigators approach to boosting exercise responsiveness in aging is to combine an exercise training prescription containing both endurance and resistance training (in alignment with DHHS guidelines) with a nitrate-enriched dietary supplement to augment the cellular, tissue, and systemic adaptations that induce myriad health benefits of exercise in older adults.",[29,354,355],"Aging Well","Healthy Aging","2026-08-05",{"date":279,"type":43},{"date":359,"type":22},"2026-11",{"date":361,"type":22},"2031-05",{"name":363,"class":50},"Florida Institute for Human and Machine Cognition",{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":59,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":383},"100555061","multidimensional-predictive-modeling-to-understand-mechanisms-of-exercise-response-heterogeneity-in-older-adults-m3ax-100555061","NCT06507189","Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)","Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults","M3AX","Inclusion Criteria:\n\n1. Male or female aged 60 or above\n2. Free of chronic disease\n3. No structured exercise program (2 or more bouts\u002Fwk) within previous 12 months\n4. Cognitively capable of providing informed consent\n\nExclusion Criteria:\n\n1. Neuromuscular or musculoskeletal disorder that would limit ability to perform the exercise and\u002For testing bouts\n2. Cardiopulmonary disorders or reduced breathing capacity\n3. Metabolic diseases including markers of liver disease (ALT \\> 52 U\u002Fl) and type 2 diabetes (HbA1C = or \\> 6.5, fasting blood glucose = or \\> 126 mg\u002Fdl)\n4. Any other disease or disorder that would influence exercise response (e.g., chronic kidney disease, dementia, current cancer diagnosis or within 2 yr remission, cerebrovascular disease)\n5. Any current infectious disease\n6. Life expectancy \\\u003C 1 year\n7. Insulin sensitizing\u002Fblood glucose lowering agents such as metformin or metabolic weight loss agents (e.g. GLP-1 agonists)\n8. High dose statin (dose equivalent of 40 mg\u002Fd or higher simvastatin)\n9. Lidocaine allergy\n10. Regular tobacco use and\u002For vaping\n11. Excessive alcohol consumption (3 drinks\u002Fd or 7 drinks\u002Fwk for females; 4 drinks\u002Fd or 14 drinks\u002Fwk for males)\n12. BMI 35.0 kg\u002Fm2 or higher\n13. Unable to commit to \\~6 months required to complete the study",{"count":373,"type":22},250,[25],"Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments that compromise healthspan and quality of life. Exercise is a multipotent treatment with promise to mitigate most aging hallmarks, but there is substantial variability in exercisƒe responsiveness. Combining endurance and resistance training in alignment with public health guidelines will be used to better understand variable exercise responsiveness in older adults with the ultimate goal of improving each older adult's capacity to attain the many health benefits of exercise.",[29,354],{"date":279,"type":43},{"date":379,"type":43},"2025-01-27",{"date":381,"type":22},"2029-08-31",{"name":363,"class":50},2,{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":18,"minAge":86,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":383},"100497073","optimization-of-a-behavioral-intervention-to-increase-physical-activity-in-older-adults-living-with-hiv-100497073","NCT05752500","Optimization of a Behavioral Intervention to Increase Physical Activity in Older Adults Living With HIV","HiActivity","Inclusion Criteria:\n\n1. HIV positive: defined by HIV antibody, detectable HIV RNA in plasma, or a note from the participant's HIV care provider.\n2. Must be on continuous antiretroviral therapy (ART) for \\> 3 months, as assessed via self-report.\n3. Low PA: defined as self-report of \\\u003C 90 minutes of moderate-vigorous PA (MVPA) per week in the previous 3 months AND less than 14 hours per week of sustained walking in the previous 4 weeks.\n4. Medically cleared for moderate PA. If participants report a) a history of cardiovascular disease including known coronary artery disease, peripheral vascular disease, heart failure, or stroke; or b) chest pain, shortness of breath, or dizziness or syncope either at rest or during activity in the past 3 months, then they must have medical clearance by a physician or primary care provider.\n5. Age 50 years or older.\n6. Proficiency in English: sufficient to engage in informed consent, understand assessments and materials provided, and engage and use Fitbit application (all materials provided in English).\n7. Capacity to consent, documented by acceptable answers in a consent \"teach-back\" process.\n8. Score of greater than 16 on the MOCA\n9. Able to ambulate without assistive devices\n10. Ability to use the FitBit application, as demonstrated to study staff.\n\nExclusion Criteria:\n\n* Exclusion Criteria\n\n  1. Medical conditions or physical or neurocognitive limitations that interfere with PA or study participation.\n  2. Hazardous substance use, assessed via a score ≥15 on the Alcohol Use Disorders Identification Test (AUDIT) or ≥6 on the Drug Abuse Screening Test (DAST).",{"count":392,"type":22},196,[25],"The goal of this clinical trial is to examine 3 interventions designed to increase physical activity in older adults with HIV. We will examine 3 potential components of an intervention package: physical activity coaching, cognitive behavioral therapy targeted toward common barriers to physical activity such as low motivation or chronic pain, and a Fitbit-based social support intervention. Our primary outcome will be physical activity, defined as steps per day. Results will guide choice of intervention components to be used in an optimized behavioral intervention.",[396,397,29],"Hiv","Physical Inactivity",{"date":399,"type":43},"2026-08-07",{"date":401,"type":43},"2023-06-21",{"date":403,"type":22},"2027-08-31",{"name":405,"class":50},"Butler Hospital",{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":86,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":23,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":51},"100649273","acupoint-stimulation-and-exercise-for-taiwanese-pre-frail-older-adults-100649273","NCT07732530","Acupoint Stimulation and Exercise for Taiwanese Pre-frail Older Adults","Exploring the Associations Among Frailty, Daily Physical Activity, Sleep, and Traditional Chinese Medicine Constitution in Taiwanese Older Adults, and Evaluating the Effects of Acupoint Stimulation Interventions","Inclusion Criteria:\n\n1. Individuals who are capable of undergoing frailty assessments.\n2. Individuals who possess effective communication skills.\n3. Aged 50 years or older.\n4. Willing to provide written informed consent, keep a 7-day sleep diary, and complete related questionnaires.\n5. Identified as pre-frail (frailty score of 1-2 points) according to the frailty phenotype criteria for the clinical trial phase.\n\nExclusion Criteria:\n\n1\\. Individuals who are unwilling or unable to wear an actigraph (wrist monitor) or undergo physical measurements.",{"count":414,"type":22},30,[25],"This study aims to explore the relationships between frailty, daily physical activity, sleep quality, and Traditional Chinese Medicine (TCM) constitutions among older adults in Taiwan. In the trial phase, a randomized controlled trial will be conducted specifically for pre-frail older adults. Participants will be randomly assigned to either the exercise training group (Vivifrail program) or the integrated group combining exercise with daytime and sleep-improving acupoint stimulation. The study evaluates the combined efficacy of these non-invasive interventions on reducing frailty severity, improving sleep, and enhancing daily physical functions.",[149,418,29],"Sleep Quality","2026-08-04",{"date":399,"type":43},{"date":422,"type":43},"2025-06-03",{"date":106,"type":22},{"name":425,"class":50},"Tainan Hospital, Ministry of Health and Welfare",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":18,"minAge":116,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":4},"100649939","changes-in-spatiotemporal-gait-parameters-during-a-digitally-assisted-self-rehabilitation-program-for-elderly-fallers--digiwalk--100649939","NCT07741994","Changes in Spatiotemporal Gait Parameters During a Digitally Assisted Self-rehabilitation Program for Elderly Fallers ( DigiWalk )","DigiWalk","Inclusion Criteria:\n\n* Patients aged 65 and older Fall at least once in the previous 3 months , requiring rehabilitation care from a physical therapist\n* Signed informed consent or consent from a third party (trusted individual, family member, or close relative)\n* Individuals physically capable of following a rehabilitation program (standard care, with or without digital assistance) and of wearing a watch\n* Individuals capable of following a self-rehabilitation program as well as the study procedures independently or with the assistance of a caregiver if needed\n* Patients enrolled in or covered by a social security program\n\nExclusion Criteria:\n\n* A person deprived of liberty by an administrative or judicial decision, a person undergoing involuntary psychiatric treatment, or an adult subject to a legal protective measure\n* Contraindications to rehabilitation programs offered following a fall (standard care, with or without digital assistance)",{"count":434,"type":22},200,[25],"Falls are a health issue that is both common among older adults (affecting 1 in 2 people each year after age 80) and serious due to their traumatic, psychological, and functionally disabling complications. The international literature shows that it is possible to prevent recurrent falls by addressing the risk factors for falls, particularly by combating a sedentary lifestyle and deconditioning through regular standing and mobility exercises as part of a rehabilitation program. As part of France's major national plan to prevent falls among older adults, and at a time when medicine is becoming increasingly personalized, prescribing a digitally assisted self-rehabilitation program for people over 65 following a fall could enable as many people as possible to benefit from rehabilitation that boosts their motivation and reduces the time spent by healthcare professionals, while ensuring high-quality follow-up care.\n\nLNA Santé, in collaboration with the Angers and Nantes University Hospitals, has developed a personalized, digitally assisted fall prevention program (the Stand'hop app) comprising three types of activities: tailored physical exercises, structured lifestyle advice, and an objective measurement of the patient's physical activity. Before moving forward with a larger-scale clinical trial to evaluate the effectiveness of this personalized, digitally assisted fall prevention program, the present study DigiWalk aims to describe changes in walking performance over 7 weeks among older adults who have experienced falls, when the program is used as an adjunct to standard care, compared to changes observed in older adults who have experienced falls and receive only standard care.",[29,438,439],"Fall","Fall Accident","2026-08-03",{"date":356,"type":43},{"date":443,"type":22},"2026-12-05",{"date":445,"type":22},"2028-06-22",{"name":447,"class":448},"University Hospital, Angers","OTHER_GOV",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":59,"sex":18,"minAge":457,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":465,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":51},"100640079","motivating-activity-through-text-communications---helping-adults-increase-movement-100640079","NCT07593677","Motivating Activity Through Text Communications - Helping Adults Increase Movement","Motivating Activity Through Text - Comparing Human and AI Messages (MATCH AIM) Trial","MATCH AIM","Inclusion Criteria:\n\n* Be 40 years of age or older\n* Own a smartphone running an Android or iOS operating system\n* Have proficiency with the English language\n* Be capable of providing informed consent\n* Be able to perform moderate physical activity without restrictions\n* Be willing to complete the entire 6-month protocol\n* Be willing to establish a 12-hour window - beginning no later than 9:45 am and ending no later than 9:45 pm - for receiving text messages.\n\nExclusion Criteria:\n\n* Residing outside of the continental United States\n* Self-reporting 90 minutes or more of moderate-to-vigorous intensity physical activity per week\n* contraindications to normal physical activity as identified on the Physical Activity Readiness Questionnaire (PAR-Q)\n* Mobility restrictions that interfere with unassisted physical activity\n* Being pregnant or planning to become pregnant during the study\n* Planning to undergo surgery during the course of the study protocol\n* Having a prior diagnosis of Alzheimer's disease or a related dementia\n* Evidence of mild cognitive impairment as indicated by a mini-Montreal Cognitive Assessment (MoCA) test score of 12 or higher\n* Concurrent participation in another study involving weight loss or physical activity\n* Failure to respond to at least 85% of Ecological Momentary Assessment (EMA) prompts during the 7-day qualification phase.","40 Years",{"count":459,"type":22},150,[25],"The goal of this clinical trial is to compare the effect of different types of text messages on physical activity levels of middle-aged and older adults and to determine whether these messages are effective in adults age 40 and older who are engaging in less than 90 minutes per week of moderate or higher intensity physical activity. The main questions it aims to answer are:\n\n* Which types of motivational messages show the greatest effects on changes in daily step counts in a 3-month precision text messaging intervention?\n* What are the effects of personalized text messages on automatic affective evaluations, habit strength (experienced automaticity), exercise identity, working memory capacity, and processing speed?\n\nParticipants will:\n\n* Wear a Fitbit activity tracker continuously for 3 months and are encouraged to continue wearing it through 6 months.\n* Wear an activPAL activity monitor on their thigh for 7-day assessment periods at the beginning of the study, at 3 months, and at 6 months.\n* Complete 3 cognitive assessments (\"brain games\") per day on their smartphone during the 7-day assessment periods at baseline, 3 months, and 6 months.\n* Be asked to set goals to increase their daily steps over the first 3 months of the study.\n* Receive up to 4 motivational text messages per day for 3 months to encourage physical activity.\n* Keep study-related apps (Fitbit app, AIM app, MetricWire app) open in the background on their smartphone.\n* Complete questionnaires at the beginning of the study, at 3 months, and at 6 months",[397,29,463,464],"Cognitive Ability","Behavior Change",[466,467,468,469,124,200,470],"physical activity","behavioral adherence","motivation","cognitive function","text messaging","2026-07-30",{"date":473,"type":43},"2026-07-31",{"date":475,"type":43},"2026-05-11",{"date":477,"type":22},"2027-08-02",{"name":479,"class":50},"University of Michigan",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":59,"sex":18,"minAge":116,"maxAge":487,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":492,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":51},"100554648","neural-control-of-gait--navigation-in-adrd-100554648","NCT06501820","Neural Control of Gait & Navigation in ADRD","Neural Control of Gait & Navigation in ADRD, Aim 3 Clinical Trial","Inclusion Criteria:\n\n* Community dwelling men and women 18-35 years old or 65-89 years old\n* Ability to walk unassisted for ten minutes\n* Willingness to undergo all testing procedures\n* English speaking Additional Inclusion Criteria for those with SCD\n* Subjective report of cognitive complaints with scores \\>16 on the Cognitive Change Index (CCI-20), a validated scale of subjective cognitive decline (Saykin et al., 2013). This scale consists of 20 items that are rated on 5 point Likert scale, where 1= \"Normal: No change compared to 5 years ago\", 3= \"Mild Problem: Some change compared to 5 years ago) and 5=\"Severe Problem: Much worse compared to 5 years ago\".)\n* No evidence of dementia or mild cognitive impairment based on cognitive screening (i.e., Montreal Cognitive Assessment (MoCA) score within normal limits for age, education and sex using the NACC Uniform Data Set (UDS) norms (Weintraub et al., 2018)\\[119\\]\n* No psychometric evidence of cognitive impairment based on performance on the Neuropsychological Battery from the NACC Unified Data Set, version 3\\[119\\]. The battery includes measures of attention, recent memory, language, visuospatial, and executive function. Norms are available for over 3600 older adults \\[119\\]. Scores on these measures cannot be lower than 1.0 SD (16th %ile) below normative values based on age, education, and gender.\n* Reading at \\> 8th grade level based on the reading subtest of the Wide Range Achievement Test- IV.\n* Global Clinic Dementia Rating (CDR) score must be 0 \\[156\\]\n* Family history of dementia\u002Fprobable Alzheimer's disease in first degree relative (parents, children, siblings)\n* Normal functional behavior in terms of daily activities, based on the Functional Activities Scale\\[122\\]\n* In line with recommendations of SCD task force (Molienueva et al., 2017)\\[116\\] an informant must be available for two reasons: a) to provide information about the participant's complaints using the informant version of the CCI-20, and b) to corroborate normal IADL's on the Functional Activity Questionnaire\\[120\\] .\n\nExclusion Criteria:\n\n* Significant medical event requiring hospitalization in the past 6 months that has the potential to contaminate data being collected (fracture, hospitalization etc.)\n* Severe visual impairment or corrected visual acuity less than 20\u002F40, which would preclude completion of the assessments\n* Inability to undergo brain imaging due to claustrophobia or implants such as pacemakers, heart valves, brain aneurysm clips, orthodontics, non-removable body jewelry, or shrapnel containing ferromagnetic metal\n* tDCS ineligibility for Aim 3 (history of epilepsy, medications that alter cortical excitability, etc.)\n* History of stroke\n* Any history of clinically diagnosed traumatic brain injury resulting in \\> 1 minute loss of consciousness\n* Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer)\n* Report of lower extremity pain due to osteoarthritis that significantly limits mobility\n* Diagnosis or treatment for rheumatoid arthritis\n* Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)\n* Unable to communicate because of severe hearing loss or speech disorder\n* Planned surgical procedure or hospitalization in the next 12 months (joint replacement, coronary artery bypass graft, etc.)\n* Severe pulmonary disease, requiring the use of supplemental oxygen\n* Terminal illness, as determined by a physician\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Is planning to move out of the area during the follow up period\n* Use of walker or wheel chair\n* Failure to provide informed consent","89 Years",{"count":273,"type":22},[25],"Brain network segregation, or independent functioning, declines with age and is associated with slower walking speed. Here, the investigators will determine the extent to which brain vestibular network segregation can be altered with bilateral vestibular cortical transcranial direct current stimulation (tDCS) in older adults with subjective cognitive decline. Participants will be randomly assigned to an active or sham stimulation condition. They will receive three, 20-minute sessions of tDCS while they are walking and performing cognitive tasks. MRI of the brain will be acquired before and after these three sessions.",[29],[124,493,494,495],"subjective cognitive decline","vestibular","mobility",{"date":473,"type":43},{"date":498,"type":43},"2025-11-13",{"date":500,"type":22},"2030-05-01",{"name":502,"class":50},"University of Florida",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":509,"eligibilityCriteria":510,"healthyVolunteers":59,"sex":18,"minAge":116,"maxAge":4,"enrollmentInfo":511,"targetDuration":513,"studyType":64,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":51},"100649968","fall-risk-in-adults-over-65-the-relevance-of-morphological-and-functional-lower-limb-asymmetries-100649968","NCT07742397","Fall Risk in Adults Over 65: The Relevance of Morphological and Functional Lower Limb Asymmetries.","Fall-risk Prevention in Adults Over 65: the Relevance of Morphological and Functional Asymmetries of the Lower Limbs.","ASY&FALL","Inclusion Criteria:\n\n* Male or female, of any ethnicity.\n* Age ≥ 65 years.\n* Cognitively intact.\n* Independent ambulation.\n* Signed and accepted informed consent to participate in all procedures required for the study.\n\nExclusion Criteria:\n\n* Previous surgical treatments for orthopedic conditions performed within the six months prior to study inclusion.\n* Severe cardiac, pulmonary, or musculoskeletal disorders that may influence the assessment outcomes.\n* Comorbidities associated with increased fall risk, such as Parkinson's disease or stroke.\n* Body Mass Index ≥ 30.0.\n* Use of medications that affect motor coordination, balance, or bone and muscle metabolism.\n* Active oncological disease.",{"count":512,"type":22},90,"1 Day","Falls among older adults represent a major public health burden. Approximately 30% of individuals aged 65 and older experience at least one fall each year. These events can lead not only to increased anxiety, depression, and reduced quality of life but also to serious injuries or even death. Key risk factors include muscle weakness, gait disturbances, and balance impairments. Lower limb asymmetry-referring to differences in strength, flexibility, composition, or functional capacity between the two legs-has emerged as a potentially important yet underexplored contributor to fall risk in the elderly population. While asymmetry is frequently studied in the context of sports and physical performance, where it may affect both injury risk and athletic outcomes, its implications for balance and mobility in older adults remain insufficiently investigated. This study aims to examine the relationship between lower limb asymmetries and fall risk, with the goal of identifying predictive indicators and informing the development of more effective fall prevention strategies. Ultimately, a better understanding of this relationship could contribute to improved quality of life for older adults and a reduction in healthcare costs associated with fall-related hospitalizations.",[29,516,517,518],"Asymmetry","Fall Risk Factors","Fall Prevention","2026-07-29",{"date":440,"type":43},{"date":522,"type":43},"2026-02-03",{"date":524,"type":22},"2028-04",{"name":526,"class":50},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":59,"sex":18,"minAge":457,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":534,"conditions":535,"keywords":538,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":383},"100624826","integrating-systematic-data-of-medicine-to-explore-the-solution-for-healthy-aging-isdha-phase-4-100624826","NCT07414680","Integrating Systematic Data of Medicine to Explore the Solution for Healthy Aging (ISDHA) Phase 4","Inclusion Criteria:\n\n* Willing to sign a written participant consent form.\n* Males or females aged 40 or above who have participated in the \"Integrated Systematic Geriatric Medical Information to Explore Solutions for Healthy Aging (Pilot Project),\" the \"Integrated Systematic Geriatric Medical Information to Explore Solutions for Healthy Aging\" master planner, or the \"Integrated Systematic Medical Information to Explore Solutions for Healthy Aging\" project (not subject to exclusion criteria).\n* Males or females aged 40-59 who have participated in health checkups for employees of Chang Gung Memorial Hospital, Formosa Plastics Group, or Chang Gung University.\n* Those with a medical record of more than one year at Chang Gung Memorial Hospital.\n* Those who have resided in Taiwan for more than 180 days in the past year.\n\nExclusion Criteria:\n\n* Individuals with severe organ abnormalities, such as: heart failure (NYHA Fc ≥ III), chronic obstructive pulmonary disease (hospitalization\u002Femergency room visit or medication adjustment within the past month due to disease worsening), decompensated cirrhosis, hemodialysis, or currently undergoing cancer treatment.\n* Individuals with a history of severe autoimmune diseases.\n* Individuals with a preliminary cognitive and mental assessment score of \\\u003C26 on the Mini-Mental State Examination (MMSE) or ≥5 on the Generalized Depression Scale (GDS).\n* Individuals (who agree to undergo brain MRI) who are deemed unsuitable for MRI after evaluation (e.g., those with pacemakers, cochlear implants, or spatial phobia).\n* Individuals who have taken antibiotics within the past month.\n* Individuals whose hearing, vision, or cognitive impairments affect communication.\n* Individuals unable to stand or walk (with a walking aid) or with unsteady gait when walking.\n* Those who have undergone follow-up outpatient assessments that may affect cognitive function, including but not limited to stroke, Parkinson's syndrome, Parkinson's dementia, epilepsy, brain tumor, or a history of mental illness such as schizophrenia, severe depression, bipolar disorder, alcohol or drug abuse, or a history of loss of consciousness due to severe head trauma.\n* Those currently diagnosed with depression and undergoing treatment.\n* Those with a past medical history confirming dementia, depression, etc..\n* Those deemed unsuitable by a physician.",{"count":373,"type":22},"This project aims to build up the comprehensive health database of geriatric medicine for middle-aged and elderly people in Taiwan.",[536,537,29],"Sleep Disturbance","Cognitive Change",[539,540,541,542],"dementia","depression","brain structure","system biology",{"date":471,"type":43},{"date":545,"type":22},"2026-09-15",{"date":547,"type":22},"2028-12-31",{"name":549,"class":50},"Chang Gung Memorial Hospital",{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":59,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":23,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":51},"100645489","smart-facial-exercise-coaching-system-for-older-adults-100645489","NCT07700654","Smart Facial Exercise Coaching System for Older Adults","Development and Testing of a Smart Facial Coaching System for Older Adults","Inclusion Criteria:\n\n* Willing to participate in this study voluntarily.\n* Able to provide written informed consent.\n* Aged 60 years or older.\n* Able to communicate in Mandarin Chinese or Taiwanese.\n\nExclusion Criteria:\n\n* Severe visual or hearing impairment.\n* Diagnosis of moderate to severe dementia.\n* Inability to communicate verbally.\n* Presence of obvious structural or pathological lesions of the face.\n* Diseases or conditions affecting swallowing function (e.g., stroke).",{"count":558,"type":22},130,[25],"Participants will participate in a 5-day facial exercise program and will be assessed at baseline, immediately after completion of the intervention, and 1 month after completion of the intervention.\n\nOlder adults aged 60 years and above who are able to communicate in Mandarin or Taiwanese and who participate in activities at adult day-care centers or community care centers will be eligible for inclusion. Individuals with severe visual or hearing impairment, moderate to severe dementia, inability to communicate verbally, obvious facial wounds or lesions, or medical conditions affecting swallowing function (e.g., stroke) will be excluded from participation.\n\nA total of approximately 130 participants will be recruited and assigned to one of two groups:\n\nIntervention Group (n ≈ 65): Participants will perform facial exercises using the Smart Facial Coaching System.\n\nControl Group (n ≈ 65): Participants will perform facial exercises by following a video-based facial exercise program.\n\nAfter providing informed consent and meeting the eligibility criteria, participants will complete baseline assessments, including structured questionnaires and the Repetitive Saliva Swallowing Test (RSST).\n\nParticipants in both groups will then perform facial exercises for five consecutive days, with each session lasting approximately 10-15 minutes.\n\nUpon completion of the 5-day facial exercise program, participants will complete post-intervention assessments, including structured questionnaires and the Repetitive Saliva Swallowing Test (RSST).\n\nOne month after completion of the intervention, participants will complete follow-up questionnaires assessing facial exercise behavior and psychosocial outcomes, which will take approximately 15-20 minutes.",[29],"2026-07-26",{"date":564,"type":43},"2026-07-28",{"date":566,"type":22},"2026-07-20",{"date":568,"type":22},"2027-05-21",{"name":570,"class":50},"National Yang Ming Chiao Tung University",{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":59,"sex":18,"minAge":142,"maxAge":117,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":581,"conditions":582,"keywords":583,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":51},"100649260","early-phase-1-the-role-of-brain-lactate-metabolism-in-neuroprotection-during-healthy-aging-100649260","NCT07731451","The Role of Brain Lactate Metabolism in Neuroprotection During Healthy Aging","Effects of Lactate on Brain Carbohydrate Metabolism in Healthy Aging","Inclusion Criteria:\n\n* Meet the American College of Sports Medicine (ACSM) physical activity guidelines for moderate-intensity aerobic activity, i.e., 150+ minutes of moderate or 75+ minutes of rigorous aerobic activity.\n* The older cohort must have adhered to these physical activity guidelines for 30+ years.\n* \"Good\" or \"Excellent\" aerobic fitness category based on ACSM standardized maximal aerobic power (V̇O2max) values for age and sex.\n\nExclusion Criteria:\n\n* Need for daily medication for chronic conditions, diagnosed heart, lung, metabolic or cerebrovascular disease, smokers, pregnancy and women in perimenopause are exclusion criteria; these will be verified with questionnaires and preliminary screening.\n* Significant carotid plaque will be excluded via ultrasound assessment.\n* Evidence of mild cognitive impairment (MCI)\n* Personal complaints of memory deficits, clinical diagnosis, or evidence from the NIH ToolBox ®V3 will be considered signs of MCI.\n* Adverse responses to maximal exercise, or an inability to complete maximal exercise during fitness screening will also be exclusion criteria.\n* known allergy to Lidocaine also cannot participate.",{"count":297,"type":22},[580],"EARLY_PHASE1","The brain's primary source of fuel is glucose. Unfortunately, the brain's ability to use glucose declines during normal aging. This decline in brain glucose metabolism makes it vulnerable to cognitive impairment and Alzheimer's disease. The brain can use another fuel source - lactate - which becomes available to the brain during exercise. The investigators have discovered that when lactate fuels the brain, brain glucose metabolism also improves. Essentially, from a metabolic angle, the brain appears younger. Recently, the investigators have shown that lactate - even in the absence of exercise - stimulates this beneficial effect on the brain. The investigators propose to compare the effects of lactate in healthy young and older adults to test whether these beneficial lactate-mediated effects persist throughout the lifespan, thereby providing a blueprint to restore youthful brain glucose metabolism.",[354,29],[584,585,586,124],"brain metabolism","lactate","exercise","2026-07-24",{"date":564,"type":43},{"date":590,"type":22},"2027-01-01",{"date":592,"type":22},"2029-01-01",{"name":594,"class":50},"Northern Arizona University",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":18,"minAge":164,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":23,"phases":605,"briefSummary":606,"conditions":607,"keywords":609,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":617,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":383},"100649116","vivifrail-exercise-program-in-nonagenarians-effects-on-function-muscle-and-cognition-100649116","NCT07731529","Vivifrail Exercise Program in Nonagenarians: Effects on Function, Muscle, and Cognition","Effects of a Multicomponent Exercise Program Based on the Vivifrail Protocol on Functional Capacity, Muscle Morphology, and Cognition in Nonagenarians: A Randomized Clinical Trial","Vivifrail","Inclusion Criteria:\n\n* Aged 90 years or older\n* Living in the community (own or family home)\n* Able to walk independently or with a walking aid (cane or walker), without third-party assistance\n* Minimum cognitive capacity to understand and perform the exercises (MMSE, education-adjusted cutoffs)\n* Adequate home conditions to perform the program\n* Availability of a family member or caregiver to support the sessions\n* Signed informed consent (with legal guardian assistance when needed)\n\nExclusion Criteria:\n\n* \\- Total inability to walk or permanent bedridden condition\n* Severe cognitive impairment preventing safe understanding and execution of exercises\n* Severe orthopedic, neurological, or rheumatological conditions preventing exercise\n* Concurrent participation in another structured exercise program\n* Anticipated unavailability (relocation, planned hospitalization, or institutionalization) during the intervention\n* Refusal to sign informed consent or absence of a legal guardian when required",{"count":604,"type":22},54,[25],"This randomized clinical trial investigates the effects of a home-based multicomponent exercise program (Vivifrail) on physical function, muscle morphology, and cognition in community-dwelling adults aged 90 years and older. Participants are randomized into three groups: Vivifrail at least twice a week, Vivifrail at least three times a week, or a control group. Outcomes are assessed at baseline, 12 weeks, and 24 weeks. The primary outcome is physical function measured by the Short Physical Performance Battery (SPPB).",[149,29,608],"Cognitive Decline",[601,610,611,612,613,614,615,616],"Multicomponent exercise","Nonagenarians","Physical function","Short Physical Performance Battery","Muscle quality","Muscle morphology","Home-based exercise",{"date":564,"type":43},{"date":619,"type":22},"2026-07",{"date":621,"type":22},"2027-09",{"name":623,"class":50},"Federal University of Rio Grande do Sul",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":59,"sex":630,"minAge":221,"maxAge":631,"enrollmentInfo":632,"targetDuration":4,"studyType":23,"phases":633,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":640,"leadSponsor":642,"locationsCount":51},"100644665","early-phase-1-beta3-adrenergic-receptors-and-cardiovascular-function-in-aging-women-100644665","NCT07674680","Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women","Inclusion Criteria:\n\n* Healthy women,\n* Assigned female at birth,\n* 18-70 years of age,\n* Body mass index \\\u003C18 or ≥30 kg\u002Fm2,\n\nExclusion Criteria:\n\n* Assigned male at birth,\n* Pregnancy,\n* Breastfeeding,\n* History of hormone replacement therapy, chemical menopause, or oophor-ectomy\n* Polycystic ovarian syndrome or Primary ovarian insufficiency,\n* Current smoking\u002FNicotine use,\n* Blood pressure ≥140\u002F90 mmHg,\n* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,\n* Nerve\u002Fneurologic disease,\n* Cardiovascular, hepatic, renal, respiratory disease,\n* Hypersensitivity to nitroglycerin,\n* Diabetes,\n* Communication barriers,","FEMALE","70 Years",{"count":273,"type":22},[580],"To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.",[636,29,637],"Women","Menopause",{"date":564,"type":43},{"date":619,"type":22},{"date":641,"type":22},"2029-05",{"name":643,"class":50},"University of Missouri-Columbia"]